BioCentury
ARTICLE | Product Development

No antigen left behind

What Amgen has added in deal for Advaxis' Listeria-delivered neoantigen platform

August 15, 2016 7:00 AM UTC

Amgen Inc. partnered with Advaxis Inc. to develop a personalized neoantigen therapy platform with potential to invoke a broad immune response by both stimulating the immune system on multiple fronts and delivering the full repertoire of a patient's potential neoepitopes.

Advaxis' ADXS-NEO uses a live attenuated form of Listeria monocytogenes bacteria to deliver a complete roster of patient-specific neoantigens directly to immune cells...